RAC 0.00% $1.61 race oncology ltd

 Race enters collaborative preclinical research program with...

  1. 286 Posts.
    lightbulb Created with Sketch. 33
     Race enters collaborative preclinical research program with The University of Newcastle to explore use of Bisantrene as a novel FTO directed treatment for melanoma Research designed to identify drug combinations that improve upon current standard of care melanoma treatment with focus on immune checkpoint resistance Project is Race’s first step under Pillar 1 of its Three Pillar strategy, designed to demonstrate Bisantrene’s potential in inhibiting FTO in humans
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.